Cargando…

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

BACKGROUND: BRAF mutation is associated with poor clinical outcome of patients with malignant tumours, and mediates resistance to chemotherapy and targeted therapy. This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rui, Xu, Ling, Qu, Xiujuan, Che, Xiaofang, Zhang, Ye, Fan, Yibo, Li, Ce, Guo, Tianshu, Hou, Kezuo, Hu, Xuejun, Drew, Lisa, Shen, Minhui, Cheung, Tony, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988692/
https://www.ncbi.nlm.nih.gov/pubmed/29755114
http://dx.doi.org/10.1038/s41416-018-0086-x
_version_ 1783329326940291072
author Ma, Rui
Xu, Ling
Qu, Xiujuan
Che, Xiaofang
Zhang, Ye
Fan, Yibo
Li, Ce
Guo, Tianshu
Hou, Kezuo
Hu, Xuejun
Drew, Lisa
Shen, Minhui
Cheung, Tony
Liu, Yunpeng
author_facet Ma, Rui
Xu, Ling
Qu, Xiujuan
Che, Xiaofang
Zhang, Ye
Fan, Yibo
Li, Ce
Guo, Tianshu
Hou, Kezuo
Hu, Xuejun
Drew, Lisa
Shen, Minhui
Cheung, Tony
Liu, Yunpeng
author_sort Ma, Rui
collection PubMed
description BACKGROUND: BRAF mutation is associated with poor clinical outcome of patients with malignant tumours, and mediates resistance to chemotherapy and targeted therapy. This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304. METHODS: Kinase activity was assessed by the AlphaScreen assay. Then, MTT assay, EdU assay, colony-formation assay and Western blot were performed to evaluate the anti-tumour effects of AZ304 in vitro. In vivo efficacy was investigated by xenograft analysis and immunohistochemistry. RESULTS: AZ304 exerted potent inhibitory effects on both wild type and V600E mutant forms of the serine/threonine-protein kinase BRAF, with IC(50) values of 79 nM and 38 nM, respectively. By suppressing ERK phosphorylation, AZ304 effectively inhibited a panel of human cancer cell lines with different BRAF and RAS genetic statuses. In selected colorectal cancer cell lines, AZ304 significantly inhibited cell growth in vitro and in vivo, regardless of BRAF genetic status. In addition, the EGFR inhibitor Cetuximab enhanced the potency of AZ304 independently of BRAF mutational status. CONCLUSIONS: The BRAF inhibitor AZ304 has broad spectrum antitumour activity, which is significantly enhanced by combination with Cetuximab in colorectal cancers in vitro and in vivo.
format Online
Article
Text
id pubmed-5988692
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59886922019-05-29 AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status Ma, Rui Xu, Ling Qu, Xiujuan Che, Xiaofang Zhang, Ye Fan, Yibo Li, Ce Guo, Tianshu Hou, Kezuo Hu, Xuejun Drew, Lisa Shen, Minhui Cheung, Tony Liu, Yunpeng Br J Cancer Article BACKGROUND: BRAF mutation is associated with poor clinical outcome of patients with malignant tumours, and mediates resistance to chemotherapy and targeted therapy. This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304. METHODS: Kinase activity was assessed by the AlphaScreen assay. Then, MTT assay, EdU assay, colony-formation assay and Western blot were performed to evaluate the anti-tumour effects of AZ304 in vitro. In vivo efficacy was investigated by xenograft analysis and immunohistochemistry. RESULTS: AZ304 exerted potent inhibitory effects on both wild type and V600E mutant forms of the serine/threonine-protein kinase BRAF, with IC(50) values of 79 nM and 38 nM, respectively. By suppressing ERK phosphorylation, AZ304 effectively inhibited a panel of human cancer cell lines with different BRAF and RAS genetic statuses. In selected colorectal cancer cell lines, AZ304 significantly inhibited cell growth in vitro and in vivo, regardless of BRAF genetic status. In addition, the EGFR inhibitor Cetuximab enhanced the potency of AZ304 independently of BRAF mutational status. CONCLUSIONS: The BRAF inhibitor AZ304 has broad spectrum antitumour activity, which is significantly enhanced by combination with Cetuximab in colorectal cancers in vitro and in vivo. Nature Publishing Group UK 2018-05-14 2018-05-29 /pmc/articles/PMC5988692/ /pubmed/29755114 http://dx.doi.org/10.1038/s41416-018-0086-x Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ma, Rui
Xu, Ling
Qu, Xiujuan
Che, Xiaofang
Zhang, Ye
Fan, Yibo
Li, Ce
Guo, Tianshu
Hou, Kezuo
Hu, Xuejun
Drew, Lisa
Shen, Minhui
Cheung, Tony
Liu, Yunpeng
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title_full AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title_fullStr AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title_full_unstemmed AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title_short AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
title_sort az304, a novel dual braf inhibitor, exerts anti-tumour effects in colorectal cancer independently of braf genetic status
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988692/
https://www.ncbi.nlm.nih.gov/pubmed/29755114
http://dx.doi.org/10.1038/s41416-018-0086-x
work_keys_str_mv AT marui az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT xuling az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT quxiujuan az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT chexiaofang az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT zhangye az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT fanyibo az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT lice az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT guotianshu az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT houkezuo az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT huxuejun az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT drewlisa az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT shenminhui az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT cheungtony az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus
AT liuyunpeng az304anoveldualbrafinhibitorexertsantitumoureffectsincolorectalcancerindependentlyofbrafgeneticstatus